RAC-US Free Study Guide! with New Update 100 Exam Questions
Get up-to-date Real Exam Questions for RAC-US UPDATED [2023]
NEW QUESTION # 10
According to ISO 14971, what is the FIRST step when developing a risk management plan for a medical device?
- A. Risk management
- B. Risk control
- C. Risk analysis
- D. Risk estimation
Answer: C
NEW QUESTION # 11
According to the GHTF, which of the following is NOT an exemption rule when evaluating the decision to report an adverse event?
- A. Adverse event caused by patient conditions
- B. Malfunction protection operated correctly
- C. Deficiency of a device found by the user prior to patient use
- D. Malfunction occurring before the end of service life of the medical device
Answer: A
NEW QUESTION # 12
A company is developing a line of products for which no ISO standard of performance is available. As a result, the company wishes to propose developing such a standard. Whom should the company contact in order to start the development of the new standard?
- A. The ISO national member body
- B. The ISO technical committee in charge of the area
- C. The ISO Secretariat
- D. The country's regulatory authority
Answer: A
NEW QUESTION # 13
In preparation for the development of a new line of products, a regulatory affairs professional is asked to prepare a short presentation for senior management. Which of the following topics is MOST important to cover?
- A. Capacity of the manufacturing facilities to fully produce the new product
- B. Potential clinical sites for the Phase III clinical trial
- C. Regulatory requirements for labeling and packaging
- D. Previous actions taken by regulatory authorities on similar products
Answer: D
NEW QUESTION # 14
Which of the following is an example of an acceptable statement for an advertisement of an approved arthritis medication?
- A. "Product X is effective for the treatment of arthritis."
- B. "Product X is safe for arthritis and without side effects."
- C. "Product X is effective in all patients with arthritis."
- D. "Product X is a guaranteed cure for arthritis."
Answer: A
NEW QUESTION # 15
Which of the following double-blind clinical trial designs would be MOST appropriate for a
Phase III study with a new product intended to treat an acute life-threatening disease with less than optimal available therapy?
- A. Placebo-controlled
- B. Dose-ranging
- C. Cross-over
- D. Active-controlled
Answer: C
NEW QUESTION # 16
In which section of the ICH Common Technical Document will the overview of clinical data appear?
- A. Module 2
- B. Module 3
- C. Module 1
- D. Module 4
Answer: A
NEW QUESTION # 17
Which of the following is the PRIMARY purpose of an audit report?
- A. To document compliance history
- B. To train sales representatives
- C. To define how to prepare new product submissions
- D. To carry out a complete review of product applications
Answer: A
NEW QUESTION # 18
During face-to-face meetings with the regulatory authority to address submission issues, what is the BEST choice for the number of company representatives who should attend?
- A. As many as required by international standards
- B. All senior management from the main office
- C. As many as government attendees
- D. The minimum number of attendees necessary to address the issues
Answer: D
NEW QUESTION # 19
Which of the following criteria is MOST appropriate to define the animal species needed for the pre-clinical toxicity testing of a biotechnology product?
- A. Proposed product route and frequency of administration
- B. Immunochemical and functional tests
- C. Biological activity with species and/or tissue specificity
- D. Proposed dose and volume of administration
Answer: C
NEW QUESTION # 20
After numerous failed attempts to decrease an identified risk in a medical device to an acceptable level, the medical device continues to have unacceptable risks. However, the development team wants to continue development. Which is the BEST recommendation to make in this situation?
- A. Discontinue the project.
- B. Redesign the device.
- C. Perform another risk-benefit analysis.
- D. Add a warning in the IFU.
Answer: B
NEW QUESTION # 21
A company is considering the development of a medical device similar to those already available. Which of the following should be evaluated FIRST when developing a clinical evaluation document?
- A. Clinical experience
- B. Literature search
- C. Adverse event reports
- D. Clinical investigations
Answer: D
NEW QUESTION # 22
Which of the following is the BEST approach for mitigating potential regulatory compliance issues at your company?
- A. Develop documented procedures for regulatory compliance processes and train personnel.
- B. Train employees on all regulatory compliance processes using state-of-the-art systems.
- C. Document any failure to follow regulatory compliance processes in employee performance reviews.
- D. Train all new employees on regulatory compliance processes and assign a mentor to them.
Answer: A
NEW QUESTION # 23
At the last internal audit, a regulatory affairs professional identified a need for a corrective action for the manufacturing process. Which of the following stakeholders should be notified FIRST?
- A. Clinical affairs
- B. Regulatory agency
- C. Quality improvement
- D. Quality assurance
Answer: D
NEW QUESTION # 24
The regulatory authority in Country X issued a request for a mandatory product recall in
Country X due to serious injuries to patients. This product also is distributed in Country Y.
What should the regulatory affairs professional of the product's manufacturer FIRST do in
Country Y?
- A. Review alt distribution records and complaints reported in Country Y.
- B. Prepare the legal team in Country Y for possible litigations.
- C. Draft a formal letter to customers in Country Y about this recall.
- D. Initiate a mandatory recall of the product in Country Y.
Answer: A
NEW QUESTION # 25
A company is developing a new medical device.
During which initial stage is it MOST appropriate (or a regulatory affairs professional to become involved?
- A. Concept development and validation
- B. Product release and validation
- C. Concept development and early technical design
- D. Early technical design and product release
Answer: C
NEW QUESTION # 26
Which of the following is NOT required to be included in a marketing application?
- A. Final printed label
- B. Evidence of fee payment
- C. Administrative forms
- D. Quality, safety, and efficacy Information
Answer: B
NEW QUESTION # 27
A company is developing a novel drug to combat AIDS. The preliminary results are very promising and include instances of complete remission. The company has been granted patents in multiple countries for the drug. The regulatory affairs professional is asked to prepare a brief report concerning potential problems for marketing of the product worldwide. Which of the following is the MOST important consideration to discuss?
- A. International import and export regulations
- B. The time frame in which the patent will expire
- C. Doha Declaration in the TRIPS Agreement
- D. The stability of the drug in all zone conditions
Answer: D
NEW QUESTION # 28
A regulatory affairs professional is asked to review and update regulatory affairs SOPs.
Which aspect of the SOP Is MOST important to consider?
- A. Expiration date
- B. Relevance to regulations
- C. Scope and level of detail
- D. Revision history
Answer: B
NEW QUESTION # 29
......
Pass RAPS RAC-US Exam in First Attempt Guaranteed: https://pass4sure.pdfbraindumps.com/RAC-US_valid-braindumps.html